GGrantIndex
← Search

ATHYMIC ANIMAL AND XENOG

$170,797P30FY2009CANIH

Case Western Reserve University, Cleveland OH

Investigators

Linked publications, trials & patents

Trial NCT05340673Trial NCT05198830Trial NCT02590107Trial NCT02535325Trial NCT02451124Trial NCT02419846Trial NCT02417948Trial NCT02392377Trial NCT02388932Trial NCT02383433Trial NCT02375477Trial NCT02354326Trial NCT02345460Trial NCT02342730Trial NCT02337465Trial NCT02327390Trial NCT02319889Trial NCT02307474Trial NCT02287636Trial NCT02252393Trial NCT02181478Trial NCT02179762Trial NCT02163317Trial NCT02158767Trial NCT02153450Trial NCT02135562Trial NCT02131207Trial NCT02129582Trial NCT02129569Trial NCT02129517Trial NCT02129218Trial NCT02128373Trial NCT02108587Trial NCT02100423Trial NCT02084147Trial NCT02082405Trial NCT02081794Trial NCT02079155Trial NCT02073097Trial NCT02073045Trial NCT02071901Trial NCT02070458Trial NCT02070419Trial NCT02055586Trial NCT02037048Trial NCT01973062Trial NCT01959490Trial NCT01959477Trial NCT01954784Trial NCT01954732Trial NCT01951885Trial NCT01939028Trial NCT01928485Trial NCT01894061Trial NCT01408043Trial NCT00991991Trial NCT00970684Trial NCT00961220Trial NCT00956475Trial NCT00952939Trial NCT00949247Trial NCT00945061Trial NCT00941720Trial NCT00941070Trial NCT00939510Trial NCT00918892Trial NCT00918788Trial NCT00918658Trial NCT00918216Trial NCT00910039Trial NCT00909662Trial NCT00908739Trial NCT00908141Trial NCT00907699Trial NCT00905086Trial NCT00900133Trial NCT00899158Trial NCT00899132Trial NCT00898573Trial NCT00898274Trial NCT00897143Trial NCT00892385Trial NCT00873600Trial NCT00873002Trial NCT00866320Trial NCT00856115Trial NCT00853021Trial NCT00842452Trial NCT00809185Trial NCT00796978Trial NCT00795678Trial NCT00769951Trial NCT00769249Trial NCT00752323Trial NCT00740961Trial NCT00736216Trial NCT00735514Trial NCT00733252Trial NCT00732745Trial NCT00732173

Abstract

The Athymic Animal &Xenograft Core Facility includes two sites, one at Case and one at the Taussig Cancer Center. The core is directed by Dr. Lili Liu and co-directed by Dr. Daniel Lindner, who oversees the Taussig facility. The core provides a pathogen-free environment for breeding and housing athymic immune deficient mice and rats for preclinical studies. A breeding colony for nude mice (NCR nu/nu) has been established to provide animals to investigators without quarantine. Investigators can also purchase other immune-deficient classes of animals, such as SCID mice, Rag 2 mice and nude rats, from external vendors and have them housed in the core for subsequent experiments after a quarantine period. Investigators use mice in the facility for studies of human tumor xenografts to test anticancer drug effects on syngeneic murine tumor implants, to determine species-specific effect of cytokines and evaluate cytotoxic T cell (CTL) response to tumor-associated antigens;to test oncogenicity of specific tumor genes on human tumor xenografts;and to perform small animal imaging to detect cancer size and location, as well as anticancer drug distribution and pharmacokinetic study in vivo. The facility provides support services for maintaining xenografts of human cancers in mouse model systems, as well as training and assistance to Cancer Center investigators;equipment and services for performing various orthotopic or ectopic injections;surgical expertise for reversible procedures;and a high-containment and safe environment for investigators using Pharmaceuticals and anticancer agents in these animal model systems. The facility helps in evaluation of new pharmacologic agents by providing data on tumor growth, metastasis, angiogenesis, and gene expression. The facility also provides consultation services to assist the investigator in all aspects of animal tumor model development.

View original record on NIH RePORTER →